Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRSN Neurosense Therapeutics Ltd

Market Closed 08-14 16:00:00 EDT

0.4531

+0.0100

+2.26%

盘后0.4823

+0.0292+6.44%

19:21 EDT

High0.4617	Low0.4383	Vol55.51K
Open0.4400	D1 Closing0.4431	Amplitude5.28%
Mkt Cap17.11M	Tradable Cap11.71M	Total Shares37.77M
T/O25.16K	T/O Rate0.21%	Tradable Shares25.85M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRSN","market":"US","secType":"STK","nameCN":"Neurosense Therapeutics Ltd","latestPrice":0.4531,"timestamp":1786737600000,"preClose":0.4431,"halted":0,"volume":55508,"hourTrading":{"tag":"盘后","latestPrice":0.4823,"preClose":0.4531,"latestTime":"19:21 EDT","volume":2409,"amount":1112.205,"timestamp":1786749684184,"change":0.0292,"changeRate":0.064445,"amplitude":0.049658},"delay":0,"changeRate":0.022568269013766663,"floatShares":25846403,"shares":37766100,"eps":-0.436593,"marketStatus":"Market Closed","change":0.01,"latestTime":"08-14 16:00:00 EDT","open":0.44,"high":0.4617,"low":0.4383,"amount":25163.66700248,"amplitude":0.05281,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.436593,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"listingDate":1639026000000,"exchange":"NASDAQ","adjPreClose":0.4431,"preHourTrading":{"tag":"盘前","latestPrice":0.4435,"preClose":0.4431,"latestTime":"07:31 EDT","volume":100,"amount":44.35,"timestamp":1786707065986,"change":0.0004,"changeRate":0.000903,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.4823,"preClose":0.4531,"latestTime":"19:21 EDT","volume":2409,"amount":1112.205,"timestamp":1786749684184,"change":0.0292,"changeRate":0.064445,"amplitude":0.049658},"volumeRatio":0.2904608386926845},"requestUrl":"/m/hq/s/NRSN/wiki","defaultTab":"wiki","newsList":[{"id":"2659506111","title":"NeuroSense Announces Shareholder Letter Availability","url":"https://stock-news.laohu8.com/highlight/detail?id=2659506111","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659506111?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:36","pubTimestamp":1786628198,"startTime":"0","endTime":"0","summary":"NeuroSense announces shareholder letter availabilityNeuroSense Therapeutics released a CEO letter to shareholders outlining near-term priorities for PrimeC in ALS.FDA clearance received to start the P","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL1jwkbl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659505181","title":"NeuroSense Targets December 2026 Canada Filing for PrimeC ALS Drug Amid Phase 3 Paragon Preparations","url":"https://stock-news.laohu8.com/highlight/detail?id=2659505181","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659505181?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:31","pubTimestamp":1786627898,"startTime":"0","endTime":"0","summary":"NeuroSense targets December 2026 Canada filing for PrimeC ALS drug amid Phase 3 PARAGON preparationsNeuroSense set plans to launch the Phase 3 PARAGON trial of PrimeC in ALS, targeting about 300 parti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL5gxNSB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658911286","title":"Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Brookdale Senior Living (BKD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658911286?lang=en_us&edition=fundamental","pubTime":"2026-08-11 23:40","pubTimestamp":1786462847,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurosense Therapeutics Ltd. (NRSN) and Brookdale Se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurosense-therapeutics-ltd-nrsn-and-brookdale-senior-living-bkd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurosense-therapeutics-ltd-nrsn-and-brookdale-senior-living-bkd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","XLV","LABU","LU2190626999.HKD","LU0842063009.USD","BK4588","HCSG","BK4581","BK4185","LU1499592464.USD","XBI","BK4585","LU0029874061.USD","BK4137","BKD","BK4139","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657865378","title":"NeuroSense sees December 2026 as filing date for NDS for PrimeC","url":"https://stock-news.laohu8.com/highlight/detail?id=2657865378","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657865378?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:35","pubTimestamp":1786030550,"startTime":"0","endTime":"0","summary":"NeuroSense (NRSN) Therapeutics announced that it is targeting December 2026 for the filing of a New Drug Submission with Health Canada for PrimeC, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-sees-december-2026-as-filing-date-for-nds-for-primec-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-sees-december-2026-as-filing-date-for-nds-for-primec-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656991253","title":"NeuroSense Therapeutics Announces Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2656991253","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656991253?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:17","pubTimestamp":1785529029,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics announces special shareholder meetingNeuroSense Therapeutics will hold a special shareholder meeting in Ra’anana, Israel on Aug. 26, 2026.Shareholders will vote on authorizing ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL7D2jht:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399194","title":"NeuroSense Amends JonesTrading Equity Distribution Agreement for up to $3.79 Million Share Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399194","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399194?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:16","pubTimestamp":1785529007,"startTime":"0","endTime":"0","summary":"NeuroSense amends JonesTrading equity distribution agreement for up to $3.79 million share salesNeuroSense amended its JonesTrading Capital on Demand sales agreement to align it with a new Form F-3 re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL4jWWF9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654192006","title":"Neurosense Therapeutics Ltd Expected to Post Breakeven Results a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2654192006","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654192006?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:03","pubTimestamp":1785236585,"startTime":"0","endTime":"0","summary":"Neurosense Therapeutics Ltd <NRSN.OQ> expected to post breakeven results a share - Earnings PreviewNeurosense Therapeutics LtdNRSN.OQNRSN.Ois expected to  report resultson July 30  for the period ending March 31 2026LSEG's mean analyst estimate for Neurosense Therapeutics Ltd is for breakeven results per share.The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Neurosense Therapeutics Ltd is $7.50, about 1,177.7% above its last closing price of $0.59This summary was machine generated July 28 at 11:03 GMT.  All figures in US dollars unless otherwise stated.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nL8N43U184:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653750737","title":"Neurosense Therapeutics - Expects to File Submission to Health Canada in Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2653750737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653750737?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:35","pubTimestamp":1784723718,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nFWN43O0D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653750401","title":"Neurosense Therapeutics Announces Press Release Availability","url":"https://stock-news.laohu8.com/highlight/detail?id=2653750401","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653750401?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:31","pubTimestamp":1784723495,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics announces press release availabilityNeuroSense flagged plans to file a New Drug Submission with Health Canada for PrimeC in ALS in coming months.Regulatory path follows a pre-s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL4vvLPY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653504027","title":"Neurosense Plans Primec New Drug Filing with Health Canada for ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2653504027","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653504027?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:31","pubTimestamp":1784723463,"startTime":"0","endTime":"0","summary":"NeuroSense plans PrimeC new drug filing with Health Canada for ALSNeuroSense plans to file a New Drug Submission with Health Canada for PrimeC to treat ALS following a Pre-NDS meeting.The submission p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL3zKdw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648668810","title":"Neurosense Therapeutics Ltd. (NRSN) Gets a Buy from Noble Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2648668810","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648668810?lang=en_us&edition=fundamental","pubTime":"2026-07-02 21:05","pubTimestamp":1782997516,"startTime":"0","endTime":"0","summary":"Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Neurosense Therapeutics Ltd. today and set a price target of $9.00. LeBoyer cover...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neurosense-therapeutics-ltd-nrsn-gets-a-buy-from-noble-financial-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neurosense-therapeutics-ltd-nrsn-gets-a-buy-from-noble-financial-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBL","BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647110370","title":"Neurosense Therapeutics Achieves Primary Endpoint in Phase 2B ALS Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2647110370","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647110370?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:34","pubTimestamp":1782743682,"startTime":"0","endTime":"0","summary":"BRIEF-Neurosense Therapeutics Achieves Primary Endpoint In Phase 2B ALS StudyJune 29 (Reuters)-Neurosense Therapeutics LtdNRSN.O:NEUROSENSE ACHIEVES PRIMARY ENDPOINT IN PHASE 2B ALS STUDY WITH STATIST","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA3QGJ3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSNW","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647377807","title":"Neurosense Rises as Nerve Disease Drug Shows Promise in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2647377807","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647377807?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:51","pubTimestamp":1782741084,"startTime":"0","endTime":"0","summary":"BUZZ-NeuroSense rises as nerve disease drug shows promise in study** U.S.-listed shares of Israel-based drug developer NeuroSense TherapeuticsNRSN.Orise 6.3% to 80 cents** NRSN says its experimental o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL4N43114F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372744","title":"NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372744","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372744?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:35","pubTimestamp":1782740117,"startTime":"0","endTime":"0","summary":"NeuroSense (NRSN) Therapeutics announced that its Phase 2b PARADIGM study of PrimeC in amyotrophic lateral sclerosis has successfully met its prima...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-says-phase-2b-paradigm-study-of-primec-in-als-met-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-says-phase-2b-paradigm-study-of-primec-in-als-met-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372942","title":"Neurosense Says Phase 2b ALS Trial Meets Primary Endpoint, Cuts Tdp-43 vs Placebo (p=0.0421)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372942","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372942?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:30","pubTimestamp":1782739841,"startTime":"0","endTime":"0","summary":"NeuroSense says Phase 2b ALS trial meets primary endpoint, cuts TDP-43 vs placebo (p=0.0421)NeuroSense reported Phase 2b PARADIGM results showing its PrimeC ALS candidate met the trial’s primary endpo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL7J57lw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647737261","title":"Neurosense Achieves Primary Endpoint in Phase 2B ALS Study with Statistically Significant Reduction of Tdp-43, the Defining Pathological Hallmark of ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2647737261","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647737261?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:30","pubTimestamp":1782739801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA3QGJ3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSNW","NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372188","title":"Neurosense Therapeutics - Primec Shows Favorable Safety Profile with no New Safety Signals over 18 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372188?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:30","pubTimestamp":1782739801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA3QGJ3T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","NRSNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646880302","title":"Neurosense Reports Positive Biomarker Findings from Phase 2 Road Proof-of-concept Study of Primec in Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2646880302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646880302?lang=en_us&edition=fundamental","pubTime":"2026-06-25 21:20","pubTimestamp":1782393600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA9PSGR4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645027612","title":"NeuroSense joins EverythingALS community event on PrimeC data in ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2645027612","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645027612?lang=en_us&edition=fundamental","pubTime":"2026-06-22 21:03","pubTimestamp":1782133397,"startTime":"0","endTime":"0","summary":"NeuroSense to join an EverythingALS community event on PrimeC titled “PrimeC - Connecting the Dots” on June 24, 2026 at 7 p.m. ET.Session led by Prof. Jeffrey Rosenfeld of Loma Linda University; discussion to include NeuroSense CEO Alon Ben-Noon.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL1x9rHt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644372150","title":"NeuroSense CEO Alon Ben-Noon acquires 250,000 shares worth USD 200,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2644372150","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644372150?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:30","pubTimestamp":1781728255,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics CEO Alon Ben-Noon reported buying 250,000 ordinary shares in a private placement.His direct holding rose to 4,534,233 ordinary shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL9QxhkH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NeuroSense CEO Alon Ben-Noon acquires 250,000 shares worth USD 200,000","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurosense-tx.com","stockEarnings":[{"period":"1week","weight":-0.0936},{"period":"1month","weight":-0.3697},{"period":"3month","weight":-0.4519},{"period":"6month","weight":-0.5643},{"period":"1year","weight":-0.6127},{"period":"ytd","weight":-0.4108}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.157004},{"month":2,"riseRate":0.6,"avgChangeRate":0.184296},{"month":3,"riseRate":0.4,"avgChangeRate":0.030043},{"month":4,"riseRate":0.6,"avgChangeRate":-0.103871},{"month":5,"riseRate":0.4,"avgChangeRate":-0.003304},{"month":6,"riseRate":0.6,"avgChangeRate":0.298631},{"month":7,"riseRate":0,"avgChangeRate":-0.259476},{"month":8,"riseRate":0.4,"avgChangeRate":-0.09998},{"month":9,"riseRate":0.5,"avgChangeRate":0.06987},{"month":10,"riseRate":0,"avgChangeRate":-0.14429},{"month":11,"riseRate":0.75,"avgChangeRate":0.430569},{"month":12,"riseRate":0.25,"avgChangeRate":-0.202897}],"exchange":"NASDAQ","name":"Neurosense Therapeutics Ltd","nameEN":"Neurosense Therapeutics Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neurosense Therapeutics Ltd,NRSN,Neurosense Therapeutics Ltd股票,Neurosense Therapeutics Ltd股票老虎,Neurosense Therapeutics Ltd股票老虎国际,Neurosense Therapeutics Ltd行情,Neurosense Therapeutics Ltd股票行情,Neurosense Therapeutics Ltd股价,Neurosense Therapeutics Ltd股市,Neurosense Therapeutics Ltd股票价格,Neurosense Therapeutics Ltd股票交易,Neurosense Therapeutics Ltd股票购买,Neurosense Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}